ClinicalTrials.gg
Active, not recruitingNCT06394414Updated Jun 25, 2026

A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

A Phase 1 interventional study of YL201 in Advanced Solid Tumors, sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.. Active, not recruiting at 25 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
187
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a phase 1, multicenter, open-label stydy to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Combination with Serplulimab with or without Platinum-based Chemotherapy in Selected Subjects with Advanced Solid Tumors conducted in China. The study will include 2 parts: a dose escalation part (Part 1) followed by a cohort expansion part (Part 2).

Part 1 will estimate the safety, tolerability and MTD/RED(s) of YL201 in combination with serplulimab with or without platinum-based chemotherapy in selected subjects with advanced solid tumors.

Part 2 will estimate the efficacy of YL201 in combination with serplulimab with or without platinum-based chemotherapy in selected subjects with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

MediLink Therapeutics (Suzhou) Co., Ltd. is the lead sponsor of 23 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1) Informed of the study before the start of the study and voluntarily sign their name and date on the form (ICF).

    2) Subjects will be enrolled in the dose-escalation phase: Advanced solid tumors, like NPC, SCLC and etc.

    3) Subjects will be enrolled in the dose-expansion phase: NPC, SCLC, NSCLC and other advanced cancer.

    4) According to the (RECIST) v1.1, there must be at least one extracranial .

    5) Archived or fresh tumor tissue samples can be provided. 6) Within 7 days before the first dose, organ and bone marrow functions must meet the requirements.

    7) performance status (ECOG PS) score of 0 or 1 by the United States of America standards.

    8) Female subjects of must agree to use highly effective measures from screening throughout the duration of the study and for at least 6 months after the last dose of the study drug. Male subjects must agree to use highly effective contraception measures from screening throughout the duration of the study and for at least 6 months after the last dose of the study drug.

    9) Subjects with expected survival ≥ 3 months. 10) Capable and willing to comply with the study protocol's scheduled visits and procedures.

Exclusion criteria

Exclusion Criteria:

  • 1) Suitable for local radical treatment. 2) Previous Drug therapy targeting B7H3. 3) Previous Drug therapy with topoisomerase I inhibitors or ADCs composed of topoisomerase I inhibitors.

    4) Prior treatment with anti-PD-(L)1, other , immune checkpoint agonists, or immunocellular therapies and other therapies targeting tumor immunity mechanisms.

    5) Toxicity from previous anticancer treatments has not resolved. 6) Concurrent enrollment in another clinical study. 7) Inadequate for prior anticancer treatment before the first dose of study drug.

    8) Underwent major surgery (excluding diagnostic surgery) or suffered serious trauma.

    9) Received allogeneic stem cell or solid organ transplant. 10) Active diseases requiring systemic treatment. 11) Received systemic . 12) to meninges or carcinomatous meningitis. 13) or spinal cord compression. 14) Uncontrolled or cardiovascular disease. 15) Clinically significant concomitant pulmonary disease. 16) With uncontrolled third-space fluid. 17) History of gastrointestinal perforation and / or fistula within 6 months prior to the first dose.

    18) Serious Infection prior to the first dose. 19) Known (HIV), virus (HBV) or virus (HCV) infection.

    20) Any other primary before the first dose of study drug. 21) A history of severe reactions to the product, inactive ingredients in the formulation, or other monoclonal antibodies.

    22) Women who are breastfeeding or pregnant as confirmed by pregnancy tests performed within 3 days before the first dose.

    23) Any illness, medical condition, organ system dysfunction, or social situation.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    Part 1: Dose escalation

    YL201 in Combination with Serplulimab with or without Platinum-based Chemotherapy

    Drug: YL201

  • Experimental
    Part2: Cohort Expansion

    YL201 in Combination with Serplulimab with or without Platinum-based Chemotherapy

    Drug: YL201

Interventions

  • DrugYL201

    YL201 (High dose, medium dose and low dose; Q3W) in Combination with Serplulimab (4.5mg/kg; Q3W) with or without Platinum(70 mg/m2; Q3W)-based Chemotherapy.

    Also known as: Serplulimab, Platinum

06

What researchers measure

Primary outcomes

  1. Evaluate the AEs in YL201 combination with serplulimab with or without platinum-based chemotherapy in advanced solid tumors

    AE: Adverse Event

    Time frame: Approximately within 36 months

  2. To determine the MTD/RED of YL201 in combination with serplulimab with or without platinum-based chemotherapy in advanced solid tumors

    maximum tolerated dose (MTD), recommended expansion dose (RED)

    Time frame: Approximately within 36 months

  3. To evaluate the efficacy of YL201 in combination with serplulimab with or without platinum-based chemotherapy in advanced solid tumors based on ORR

    objective response rate (ORR)

    Time frame: Approximately within 36 months

  4. To determine the RP2D of YL201 in combination with serplulimab with or without platinum-based chemotherapy in advanced solid tumors based on ORR

    recommended Phase 2 dose (RP2D)

    Time frame: Approximately within 36 months

Secondary outcomes

  1. To evaluate the AUC of YL201 combination therapy

    area under the curve (AUC)

    Time frame: Approximately within 36 months

  2. To evaluate the Cmax of YL201 combination therapy

    peak concentration (Cmax)

    Time frame: Approximately within 36 months

  3. To evaluate the Ctrough of YL201 combination therapy

    trough concentration (Ctrough)

    Time frame: Approximately within 36 months

  4. To evaluate the CL of YL201 combination therapy

    clearance rate (CL)

    Time frame: Approximately within 36 months

  5. To evaluate the Vd of YL201 combination therapy

    volume of distribution (Vd)

    Time frame: Approximately within 36 months

  6. To evaluate the t1/2 of YL201 combination therapy

    half-life time (t1/2)

    Time frame: Approximately within 36 months

  7. To evaluate the DpR of YL201 combination therapy

    depth of response (DpR); assessed based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Approximately within 36 months

  8. To evaluate the DCR of YL201 combination therapy

    disease control rate (DCR); assessed based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Approximately within 36 months

  9. To evaluate the DoR of YL201 combination therapy

    duration of response (DoR); assessed based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Approximately within 36 months

  10. To evaluate the TTR of YL201 combination therapy

    time to response (TTR); assessed based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Approximately within 36 months

  11. To evaluate the PFS of YL201 combination therapy

    progression-free survival (PFS); assessed based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Approximately within 36 months

  12. To evaluate the OS of YL201 combination therapy

    Overall survival (OS)

    Time frame: Approximately within 36 months

  13. To evaluate the immunogenicity of YL201 combination therapy

    Incidence of anti-YL201 antibodies

    Time frame: Approximately within 36 months

  14. To assess the expression level of B7H3 and PD-L1 in Tumor tissue

    Time frame: Approximately within 36 months

07

Study locations

25 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Apr 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2024
First posted
May 1, 2024
StartActual
Apr 17, 2024
Primary completionEst.
Apr 29, 2027
CompletionEst.
Apr 29, 2030
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06394414
Responsible party
Sponsor
First posted
May 1, 2024
Start date
Apr 17, 2024
Primary completion
Apr 29, 2027 (estimated)
Completion
Apr 29, 2030 (estimated)
Last update
Jun 25, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tambotatug pelitecan

Start the discussion